TLDR
- Shares of Olema Pharmaceuticals (OLMA) surged 8.5% Monday following a fourth-quarter EPS that narrowly exceeded projections, posting a loss of $0.50 compared to the anticipated $0.51.
- The biotech firm recorded a GAAP net loss totaling $46.1 million during Q4 2025, with full-year losses reaching $162.5 million.
- Stifel maintained its Buy recommendation with a $48 price target post-earnings, highlighting sufficient cash reserves extending through mid-2028.
- Recent setbacks in Roche’s persevERA study, which failed its primary endpoint, have sparked concerns regarding Olema’s OPERA-02 clinical trial trajectory.
- Wall Street consensus rates the stock a “Moderate Buy” with a mean price target of $41, although shares have declined 41% year-to-date despite soaring 234% over the past twelve months.
Shares of Olema Pharmaceuticals (OLMA) advanced 8.5% during Monday’s trading session after delivering fourth-quarter financial results that marginally surpassed analyst projections. The stock touched an intraday peak of $16.07 before closing near $15.96, representing a gain from the previous close of $14.71.
Olema Pharmaceuticals, Inc., OLMA
The biopharmaceutical company disclosed a quarterly loss of $0.50 per share for Q4 2025, narrowly topping the Street’s consensus projection of a ($0.51) loss by one cent. While the margin was slim, it proved sufficient to drive investor enthusiasm.
For fiscal year 2025 in its entirety, Olema recorded a GAAP net loss totaling $162.5 million. The fourth quarter alone contributed $46.1 million to that deficit. Management opted not to host an earnings conference call alongside the financial release.
Despite continued losses, the stock has experienced significant volatility. OLMA shares have skyrocketed 234% over the trailing twelve-month period, yet retreated 41% year-to-date prior to Monday’s uptick.
Trading activity registered 518,220 shares changing hands — substantially lighter than the typical daily volume of approximately 1.6 million shares. The subdued volume may signal investor hesitation rather than strong conviction behind the rally.
Analyst Reaction
Stifel promptly responded to the earnings release by reaffirming its Buy rating and $48 price objective. The investment firm emphasized Olema’s financial runway extending through mid-2028 as a significant advantage, providing adequate capital to reach multiple development milestones ahead of palazestrant’s anticipated commercial debut.
Palazestrant is currently in development for treating second- and third-line metastatic breast cancer patients, with market entry projected for 2027.
The broader Street perspective remains optimistic. Ten analysts maintain Buy recommendations on the shares, with one holding a neutral stance and one rating it a Sell. The consensus price objective stands at $41.00 — representing substantial upside from current trading levels.
Oppenheimer reaffirmed its Outperform stance on March 9th. JPMorgan elevated its price target from $29 to $32 last November while maintaining an Overweight rating. TD Cowen similarly holds a Buy recommendation, noting palazestrant’s superior target engagement compared to rival therapies.
H.C. Wainwright reduced its target to $38 but preserved its Buy rating in response to recent clinical developments.
The Roche Factor
Earlier this month, Roche disclosed that its persevERA clinical study — assessing giredestrant combined with palbociclib for first-line metastatic breast cancer — failed to achieve statistical significance for its primary progression-free survival endpoint. While a favorable numerical trend emerged, the statistical miss carries implications.
The persevERA outcome is broadly interpreted as a potential indicator for Olema’s ongoing Phase 3 OPERA-02 study, which is evaluating palazestrant. Top-line results from OPERA-02 aren’t anticipated before 2028.
Stifel noted that Roche’s complete persevERA dataset will likely receive presentation at ASCO 2026, potentially serving as the next significant catalyst — or obstacle — for OLMA shares.
Regarding balance sheet strength, Olema maintains more cash than outstanding debt, sporting a current ratio of 8.03. The 50-day moving average rests at $24.18, considerably above Monday’s price levels.
Institutional stakeholders control 91.78% of outstanding shares. Company insiders, conversely, have been net sellers — divesting approximately 805,501 shares valued at roughly $23 million during the past three months.
The company’s market capitalization currently stands at approximately $1.09 billion.
